Biomerieux (France) Performance
| BIM Stock | EUR 115.80 0.10 0.09% |
On a scale of 0 to 100, Biomerieux holds a performance score of 13. The firm shows a Beta (market volatility) of 0.24, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Biomerieux's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biomerieux is expected to be smaller as well. Please check Biomerieux's downside variance, daily balance of power, and the relationship between the maximum drawdown and skewness , to make a quick decision on whether Biomerieux's price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Biomerieux SA are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak primary indicators, Biomerieux sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 371.3 M | |
| Total Cashflows From Investing Activities | -307.3 M |
Biomerieux |
Biomerieux Relative Risk vs. Return Landscape
If you would invest 10,150 in Biomerieux SA on December 21, 2024 and sell it today you would earn a total of 1,430 from holding Biomerieux SA or generate 14.09% return on investment over 90 days. Biomerieux SA is generating 0.2249% of daily returns assuming 1.3223% volatility of returns over the 90 days investment horizon. Simply put, 11% of all stocks have less volatile historical return distribution than Biomerieux, and 96% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Biomerieux Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biomerieux's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biomerieux SA, and traders can use it to determine the average amount a Biomerieux's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1701
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BIM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.32 actual daily | 11 89% of assets are more volatile |
Expected Return
| 0.22 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Biomerieux is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biomerieux by adding it to a well-diversified portfolio.
Biomerieux Fundamentals Growth
Biomerieux Stock prices reflect investors' perceptions of the future prospects and financial health of Biomerieux, and Biomerieux fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biomerieux Stock performance.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 11.4 B | |||
| Shares Outstanding | 118.37 M | |||
| Price To Earning | 35.41 X | |||
| Price To Book | 3.27 X | |||
| Price To Sales | 3.28 X | |||
| Revenue | 3.38 B | |||
| EBITDA | 1.01 B | |||
| Cash And Equivalents | 280.1 M | |||
| Cash Per Share | 2.38 X | |||
| Total Debt | 362.8 M | |||
| Debt To Equity | 27.30 % | |||
| Book Value Per Share | 29.31 X | |||
| Cash Flow From Operations | 811.1 M | |||
| Earnings Per Share | 4.66 X | |||
| Total Asset | 4.62 B | |||
| Retained Earnings | 949 M | |||
| Current Asset | 1.1 B | |||
| Current Liabilities | 689 M | |||
About Biomerieux Performance
By analyzing Biomerieux's fundamental ratios, stakeholders can gain valuable insights into Biomerieux's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biomerieux has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biomerieux has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
bioMrieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company was formerly known as B-D Mrieux. bioMrieux S.A. was founded in 1963 and is based in Marcy lEtoile, France. bioMrieux S.A. is a subsidiary of Institut Mrieux SA. BIOMERIEUX operates under Diagnostics Research classification in France and is traded on Paris Stock Exchange. It employs 11200 people.Things to note about Biomerieux SA performance evaluation
Checking the ongoing alerts about Biomerieux for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biomerieux SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 64.0% of the company shares are held by company insiders |
- Analyzing Biomerieux's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biomerieux's stock is overvalued or undervalued compared to its peers.
- Examining Biomerieux's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biomerieux's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biomerieux's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biomerieux's stock. These opinions can provide insight into Biomerieux's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biomerieux Stock analysis
When running Biomerieux's price analysis, check to measure Biomerieux's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomerieux is operating at the current time. Most of Biomerieux's value examination focuses on studying past and present price action to predict the probability of Biomerieux's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomerieux's price. Additionally, you may evaluate how the addition of Biomerieux to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |